Primary Lung Tumors

Primary lung tumors are neoplasms originating from the pulmonary parenchyma, bronchial epithelium, or bronchial glands, excluding metastatic disease from other sites. In dogs and cats, the most common primary lung tumor is pulmonary adenocarcinoma (bronchoalveolar carcinoma), followed by squamous cell carcinoma, adenosquamous carcinoma, and less frequently, carcinoid, sarcoma, and lymphoma. These tumors typically arise in the peripheral lung fields, often in the caudal lung lobes, and can be solitary or multiple. Surgical resection via lobectomy is the mainstay of treatment for localized disease, with the goal of complete excision and long-term control. The surgical approach, extent of resection, and perioperative management are critical for successful outcomes.

The exact etiology of primary lung tumors in dogs and cats is largely unknown, but several factors have been implicated. Chronic inflammation and fibrosis may predispose to pulmonary adenocarcinoma, as seen in humans with pulmonary fibrosis. Exposure to environmental carcinogens, such as secondhand tobacco smoke, has been associated with an increased risk of lung cancer in dogs, particularly in breeds with long noses (dolichocephalic). Genetic mutations, including activation of oncogenes (e.g., K-ras) and inactivation of tumor suppressor genes (e.g., p53), have been identified in canine pulmonary adenocarcinomas. Viral etiologies have been suggested but not confirmed. In cats, primary lung tumors are less common, and no specific breed or environmental predispositions have been definitively identified, though feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) infections may impair immune surveillance.

Primary lung tumors are relatively uncommon in dogs and cats, accounting for approximately 1% of all neoplasms in dogs and 0.5% in cats. The median age at diagnosis is 10-12 years in dogs and 12-14 years in cats. No strong sex predilection is reported, though some studies suggest a slight female predominance in dogs. Brachycephalic breeds, such as Boxers and Bulldogs, may have a higher risk, possibly due to chronic respiratory inflammation. In cats, no breed predilection is consistently reported. Large-breed dogs may present with more advanced disease due to delayed detection. The incidence appears to be increasing, possibly due to improved diagnostic imaging and increased longevity of pets.

Primary lung tumors arise from the epithelial cells of the bronchial tree or alveolar lining. They grow locally, invading the pulmonary parenchyma and potentially spreading to regional lymph nodes (tracheobronchial, sternal) and distant sites (brain, bone, liver, adrenal glands). The tumor can cause bronchial obstruction, leading to atelectasis, post-obstructive pneumonia, and dyspnea. As the tumor enlarges, it may invade the pleura, causing pleural effusion, or the thoracic wall, leading to pain and lameness (if there is hypertrophic osteopathy). Paraneoplastic syndromes, such as hypertrophic osteopathy (Marie's disease), can occur, characterized by periosteal new bone formation along the distal limbs. The tumor's growth rate and metastatic potential vary with histologic type and grade; well-differentiated adenocarcinomas have a better prognosis than poorly differentiated or sarcomatous tumors.

Predisposing factors for primary lung tumors include advanced age, as most tumors occur in older animals. Chronic exposure to environmental carcinogens, such as tobacco smoke, may increase risk. Chronic inflammatory lung diseases, such as chronic bronchitis or pulmonary fibrosis, may predispose to neoplastic transformation. Genetic factors, including breed-specific susceptibilities, may play a role, though specific genes have not been fully characterized. Immunosuppression, whether from viral infections (FeLV, FIV) or chronic corticosteroid use, may impair tumor surveillance. Obesity and poor nutritional status may also contribute to overall cancer risk, though specific evidence is lacking.

Clinical signs of primary lung tumors are often insidious and may be absent in early stages. Common signs include chronic cough (often non-productive), exercise intolerance, dyspnea, tachypnea, and hemoptysis (rare). Systemic signs such as lethargy, anorexia, and weight loss may occur, especially with advanced disease. Paraneoplastic syndromes, such as hypertrophic osteopathy, may cause lameness and limb swelling. On physical examination, auscultation may reveal decreased lung sounds, crackles, or wheezes over the affected lobe. In cases with pleural effusion, lung sounds may be muffled ventrally. Digital clubbing (hypertrophic osteopathy) may be noted on limb palpation. Neurologic signs may occur if brain metastasis is present.

Differential diagnoses for primary lung tumors include: 1) Metastatic lung tumors (from mammary, bone, or other primary sites) - distinguished by history, multiple nodules, and identification of primary tumor. 2) Benign pulmonary nodules (e.g., granulomas, abscesses) - may appear similar on radiographs but often have a more benign clinical course. 3) Pulmonary abscess or pneumonia - typically associated with fever, leukocytosis, and response to antibiotics. 4) Bronchial foreign body - may cause chronic cough and focal lung changes. 5) Pulmonary thromboembolism - acute onset dyspnea, risk factors, and imaging findings. 6) Lung lobe torsion - often associated with pleural effusion and specific radiographic signs. 7) Fungal pneumonia (e.g., blastomycosis, histoplasmosis) - endemic areas, systemic signs, and serologic testing. 8) Parasitic granulomas (e.g., dirofilariasis) - heartworm testing and eosinophilia.

The diagnostic algorithm for suspected primary lung tumor begins with a thorough history and physical examination, including thoracic auscultation and palpation of the limbs for hypertrophic osteopathy. Thoracic radiographs (three views: right and left lateral, ventrodorsal) are the initial imaging modality, revealing a solitary or multiple pulmonary nodules/masses. If a solitary mass is identified, thoracic CT is recommended for better characterization, assessment of lymph node involvement, and surgical planning. CT is more sensitive for detecting small nodules and evaluating the mediastinum. Fine-needle aspiration (FNA) of the lung mass, guided by ultrasound or CT, can provide cytologic diagnosis, though it may be nondiagnostic. Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy may be helpful for endobronchial lesions. If pleural effusion is present, thoracocentesis with fluid analysis and cytology may reveal neoplastic cells. Preoperative staging includes abdominal ultrasound to rule out metastasis, and possibly brain MRI if neurologic signs are present. Surgical biopsy (via thoracotomy or thoracoscopy) is often necessary for definitive diagnosis and treatment.

Complete blood count (CBC) may reveal leukocytosis due to inflammation or infection, or eosinophilia in cases of paraneoplastic syndromes. Serum biochemistry may show hypercalcemia (in some cases of adenocarcinoma), elevated liver enzymes (if metastasis), or hypoalbuminemia (chronic disease). Urinalysis is generally unremarkable. Coagulation panel (PT, aPTT, platelet count) is recommended preoperatively to assess bleeding risk. Arterial blood gas analysis may show hypoxemia if pulmonary function is compromised. Inflammatory biomarkers such as C-reactive protein (CRP) may be elevated. Thoracocentesis fluid analysis: if pleural effusion is present, it is typically a modified transudate or exudate, and cytology may reveal neoplastic cells (carcinomatous cells often form clusters).

Thoracic radiographs: Primary lung tumors typically appear as a solitary, well-circumscribed soft tissue nodule or mass, most commonly in the caudal lung lobes. They may be cavitary or mineralized. Multiple nodules suggest metastasis. Pleural effusion may be present. Thoracic CT: CT provides superior detail, allowing assessment of tumor size, location, invasion into adjacent structures (chest wall, mediastinum), and identification of enlarged tracheobronchial or sternal lymph nodes. CT is also useful for detecting small nodules not visible on radiographs. MRI: MRI is rarely used for lung tumors but may be helpful for evaluating mediastinal invasion or brain metastasis. Ultrasound: Transthoracic ultrasound can guide FNA or biopsy of peripheral masses and assess pleural effusion. Echocardiography may be performed to rule out cardiac metastasis or concurrent heart disease.

Cytology from FNA of lung masses may show clusters of epithelial cells with criteria of malignancy (anisocytosis, anisokaryosis, prominent nucleoli). However, cytology may be nondiagnostic due to necrosis or hemorrhage. Histopathology of the resected lobe is essential for definitive diagnosis and grading. Pulmonary adenocarcinomas are classified as papillary, bronchioloalveolar, solid, or mixed. Histologic grading (well, moderate, poorly differentiated) and presence of vascular invasion are important prognostic indicators. Surgical margins should be evaluated for completeness of excision. Immunohistochemistry may be used to differentiate primary lung tumors from metastatic lesions (e.g., thyroid transcription factor-1 (TTF-1) positivity supports pulmonary origin).

Surgical resection is the treatment of choice for primary lung tumors without evidence of metastasis. The standard procedure is lobectomy, either via intercostal thoracotomy or thoracoscopy. Complete lobectomy is recommended over partial lobectomy to ensure clean margins. The surgical approach depends on the lobe affected: for right cranial and middle lobes, a right lateral thoracotomy at the 4th or 5th intercostal space; for right caudal lobe, a right lateral thoracotomy at the 5th or 6th intercostal space; for left cranial and caudal lobes, a left lateral thoracotomy at the 5th or 6th intercostal space. Alternatively, median sternotomy allows access to both hemithoraces and is preferred for multiple lesions or bilateral disease. The hilus is dissected, and the pulmonary artery, vein, and bronchus are individually ligated. Vascular staplers (e.g., TA stapler) or suture ligation (e.g., 2-0 or 3-0 polydioxanone) can be used. A bronchial stump closure is performed with sutures or staples. A thoracostomy tube is placed for postoperative drainage. In cases with enlarged tracheobronchial lymph nodes, lymph node extirpation is recommended. Adjuvant chemotherapy (e.g., carboplatin, doxorubicin) may be considered for high-grade tumors or incomplete margins, though its benefit is not well-established. Palliative options for non-surgical candidates include stereotactic radiation therapy.

The prognosis for primary lung tumors is variable and depends on tumor stage, histologic grade, and completeness of excision. Dogs with a solitary, well-differentiated adenocarcinoma and no lymph node involvement have a median survival time (MST) of over 1 year, with some living 2-3 years. Poorly differentiated tumors, lymph node metastasis, and large tumor size (>5 cm) are negative prognostic indicators. Cats generally have a poorer prognosis, with MST of 6-12 months even after surgery. The presence of clinical signs at diagnosis is also associated with a worse prognosis. Hypertrophic osteopathy may resolve after tumor removal. Overall, the 1-year survival rate for dogs after surgical resection is approximately 50-60%, and the 2-year survival rate is 20-30%.

Postoperative follow-up includes monitoring for complications such as pneumothorax, hemorrhage, and infection. Thoracostomy tube is typically removed 12-24 hours after surgery if no air leak or significant fluid accumulation. Sutures are removed 10-14 days postoperatively. Thoracic radiographs are recommended at 1, 3, 6, and 12 months after surgery to monitor for recurrence or metastasis. CT may be performed if recurrence is suspected. Physical examination should include assessment of respiratory function and palpation of the limbs for hypertrophic osteopathy. Activity restriction is advised for 2-4 weeks postoperatively, with gradual return to normal exercise. Long-term monitoring for paraneoplastic syndromes is important.

Pearls: 1) Always obtain three-view thoracic radiographs to avoid missing small nodules. 2) CT is essential for surgical planning, especially for assessing lymph node involvement and invasion. 3) For peripheral masses, consider thoracoscopic lobectomy to reduce morbidity. 4) Ligate the pulmonary vessels individually to prevent hemorrhage. 5) Use a stapler for bronchial closure to reduce air leak. 6) Place a thoracostomy tube before closing the thorax to manage postoperative pneumothorax. Pitfalls: 1) Failure to perform a complete lobectomy may leave tumor at the margin. 2) Incomplete staging may miss metastasis, leading to unnecessary surgery. 3) Overlooking enlarged lymph nodes may result in incomplete resection. 4) Postoperative pneumothorax can be life-threatening if not managed with a chest tube. 5) Do not delay surgery for FNA if the mass is highly suspicious, as FNA may cause pneumothorax.

Perioperative antimicrobial prophylaxis: Cefazolin (22 mg/kg IV) administered 30 minutes before incision and repeated every 90 minutes during surgery. Postoperative analgesia: Opioids (e.g., hydromorphone 0.05-0.1 mg/kg IV q4-6h, or fentanyl CRI at 2-5 mcg/kg/h) for 24-48 hours. NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h, or meloxicam 0.1 mg/kg PO q24h) may be started after extubation if no contraindications. Local anesthesia: Intercostal nerve blocks with bupivacaine (1-2 mg/kg) at the incision site and adjacent intercostal spaces. For refractory pain, consider epidural analgesia with morphine (0.1 mg/kg) and bupivacaine (0.5-1 mg/kg). Antiemetics (e.g., maropitant 1 mg/kg IV q24h) may be used if needed. Chemotherapy protocols: For high-grade tumors, carboplatin (300 mg/m² IV q3-4 weeks) or doxorubicin (30 mg/m² IV q3 weeks) may be considered, with dose adjustments based on hematologic monitoring.

Several studies have evaluated prognostic factors for primary lung tumors in dogs. A landmark study by McNiel et al. (1997) found that tumor size (>5 cm), lymph node metastasis, and histologic grade were significant predictors of survival. Another study by Polton et al. (2008) reported that dogs with stage I (no lymph node involvement) had a median survival of 790 days, compared to 240 days for dogs with stage II/III. A recent study by Turek et al. (2020) evaluated thoracoscopic lobectomy and found it to be a safe and effective alternative to open thoracotomy, with shorter hospital stays and similar outcomes. For cats, a study by Hahn et al. (2007) reported a median survival of 115 days after surgery, with negative prognostic factors including clinical signs and high histologic grade. Adjuvant chemotherapy has not been shown to significantly improve survival in dogs with completely resected tumors, but may be considered for high-risk cases. Stereotactic radiation therapy has shown promise for non-surgical candidates, with local control rates of 80-90% in some studies.